Skip to main content
. 2025 Jun 26;17(6):102722. doi: 10.4330/wjc.v17.i6.102722

Table 2.

Comparison table of treatment options for sinus of Valsalva aneurysms

Interventions
Recommendations
Advantages
Disadvantages
Medical management Insufficient for definitive treatment. Blood pressure control with antihypertensives such as angiotensin-converting enzyme inhibitors, beta-blockers, or calcium channel blockers to reduce aortic wall stress should be used as a temporary measure until definitive surgical repair or transcatheter closure can be done Reduces the chances of rupture for cases of unruptured SoVAs Not definitive treatment
Surgical repair Surgery remains the definitive treatment for SoVAs. Recommended for symptomatic, large, or rapidly progressive aneurysms and all ruptured aneurysms. The 2010 American Guidelines for Thoracic Aortic Disease recommend considering surgical repair for aneurysms greater than 5.5 cm, greater than 5 cm in patients with BAVs, greater than 4.5 cm in the setting of connective tissue disease, or a yearly growth rate that exceeds 0.5 cm Can address concurrent cardiac issues such as VSDs or aortic valve dysfunction Higher risk for complications such as bleeding, infection, or heart failure. Additionally, surgical repair prolongs hospital stay and recovery times compared to TCC
Transcatheter closure Emerging minimally invasive technique used to treat both ruptured and unruptured aneurysms Advantages include reduced surgical risks, avoiding heart surgery, and shortened hospital length and recovery times Has potential complications such as residual shunt, embolization, or device malposition, which are generally manageable

SoVA: Sinus of Valsalva aneurysm; BAVs: Bicuspid aortic valve; VSDs: Ventricular septal defects; TCC: Transcatheter closure.